



JAGSONPAL PHARMACEUTICALS LIMITED

**Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015,
Haryana (India)**

**Ph.: +91 124 4406710; E-mail: cs@jagsonpal.com; Website: www.jagsonpal.com
CIN NO. L74899DL1978PLC009181**

July 25, 2024

The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	The Department of Corporate Services- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
---	--

Subject: Intimation as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Signing of Binding Agreement for sale of Company’s Faridabad facility

Dear Sir/ Madam,

Further to our intimation dated November 3, 2023 on the proposed divestment of Company’s Faridabad facility, we now wish to inform you that the Company has entered into an Agreement to Sale to divest the said Facility.

Disclosure as required under Regulation 30 of SEBI LODR read with Schedule III, Part A. A.1 is enclosed herewith under ‘Annexure – I’.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For **Jagsonpal Pharmaceuticals Limited**

Abhishek Joshi
Company Secretary & Compliance Officer



JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015,
Haryana (India)

Ph.: +91 124 4406710; E-mail: cs@jagsonpal.com; Website: www.jagsonpal.com
CIN NO. L74899DL1978PLC009181

Annexure I

Details Required under Regulation 30 of SEBI (LODR) Regulations, 2015, pursuant to SEBI Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Disclosure for sale of Land

Sr. No.	Particulars	Remarks
a)	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	Nil - The facility was not operational and did not contribute to any revenue in the last year
b)	Date on which the agreement for sale has been entered into	July 25, 2024
c)	The expected date of completion of sale/disposal;	On or before October 31, 2024
d)	Consideration received from such sale/disposal;	Rs. 41 crores (proposed to be received)
e)	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	Regalia Laminates LLP having its registered office at MCD Building B Gupta Road Paharganj New Delhi, Delhi -110055 The Buyers does not belong to the Promoter/ Promoter Group/ Group Companies.
f)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	The transaction does not fall within the purview of related party transactions
g)	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	Not applicable
h)	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not applicable